EIKN

Eikon Therapeutics, Inc.

Tremor tracks 6 of its cancer trials.

Company-wide warning signs

These add points to every one of this company's trials.

None right now.

Trials

EIKNEikon Therapeutics
0Calm
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Signing up patientsPhase 2/3750 patientsMain results: Dec 31, 2035
EIKNEikon Therapeutics
0Calm
EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
Signing up patientsPhase 1/2160 patientsMain results: Mar 2029
EIKNEikon Therapeutics
0Calm
Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.
Signing up patientsPhase 2/3740 patientsMain results: Dec 2035
EIKNEikon Therapeutics
0Calm
A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors
Signing up patientsPhase 1/2156 patientsMain results: Jun 1, 2027
EIKNEikon Therapeutics
0Calm
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
Running, no new patientsPhase 270 patientsMain results: Dec 2026
EIKNEikon Therapeutics
0Calm
A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors.
Signing up patientsPhase 1/2130 patientsMain results: Dec 2028

Key executives leaving

From the last 12 months of the company's SEC reports.

None found.

Insider trades (last 6 months)

“Insiders” are executives, board members, and big shareholders. Many of their sales are pre-planned: scheduled months ahead under a legal plan (called 10b5-1), so they usually say little. Tremor only counts sales that weren't pre-planned.

0 sales (0 not pre-planned) · 1 purchase

Column Group IV GP, LPLarge shareholder · Sep 3, 2026Bought 89,200 sharesabout $1.0 million ·

Recent SEC filings

Public companies must report important news and their finances to the SEC, the US agency that oversees the stock market.

Money left

Coming soon: how many months of cash the company has, from its quarterly reports.